Keep up to date with stayble’s latest news and events

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

NB: This is an English convenience translation of this press release. In case of any discrepancy, the correct version is the Swedish original “Stayble Therapeutics AB offentliggör prospect med anledning av företrädesemissionen”.

Today, March 24th, 2023, the subscription period of Stayble Therapeutics AB’s (”Stayble” or ”the Company”) rights issue of shares with preferential right for existing shareholders (“the Rights Issue”). The public is also invited to subscribe for shares. The subscription period lasts up to and including April 12th, 2023. The Rights Issue, if fully subscribed, can provide the Company a maximum of approximately MSEK 35.2, before deduction of transaction related costs. Prospectus and a teaser summary are available at the Company’s (www.staybletherapeutics.com), Sedermera Corporate Finance AB’s (www.sedermera.se) and Nordic Issuing AB’s (www.nordic-issuing.se) respective web pages. The investment documents are also available at Stayble’s web page for the Rights Issue (https://www.foretradesemission.staybletherapeutics.se/).

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

NB: This is an English convenience translation of this press release. In case of any discrepancy, the correct version is the Swedish original “Stayble Therapeutics AB erhåller ytterligare teckningsförbindelser och vederlagsfri toppgaranti I förestående företrädesemission”.

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby informs that the Company has received additional pre-subscription commitments as well as an additional remuneration-free top-down underwriting commitment regarding the upcoming rights issue from the Company’s single largest shareholders Chalmers Ventures AB, Robert Joki and Almi Invest Västsverige AB equal to approximately 3.7 MSEK. Through the remuneration-free top-down underwriting commitment by Almi Invest Västsverige AB, the rights issue is cover up to approximately 85 percent (approximately MSEK 30) by pre-subscription and underwriting commitments.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

NB: This is an English convenience translation of this press release. In case of any discrepancy, the correct version is the Swedish original “Stayble Therapeutics AB offentliggör prospect med anledning av företrädesemissionen”.

Today, March 17th, 2023, the Board of Directors of Stayble Therapeutics AB (“Stayble” or the “Company”) publishes the prospectus relating to the Company’s upcoming rights issue of shares, for which the subscription period starts on Friday, March 24th, 2023 (the “Rights Issue”). The prospectus has today been approved and registered by Swedish Financial Supervisory Authority and will be made available on the Swedish Financial Supervisory Authority’s website (www.fi.se). The prospectus is also available, starting today, on the websites of the Company (www.staybletherapeutics.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se).

Idag den 16 mars 2023 hölls extra bolagsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet.